

# Victor Mangas-Sanjuan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3594246/publications.pdf>

Version: 2024-02-01

25  
papers

281  
citations

1162367

8  
h-index

940134

16  
g-index

25  
all docs

25  
docs citations

25  
times ranked

461  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration. <i>Pharmaceutics</i> , 2019, 11, 365.  | 2.0 | 86        |
| 2  | Semimechanistic Cell-Cycle Typeâ€‘Based Pharmacokinetic/Pharmacodynamic Model of Chemotherapy-Induced Neutropenic Effects of Diflomotecan under Different Dosing Schedules. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 354, 55-64.     | 1.3 | 26        |
| 3  | A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability. <i>European Journal of Medicinal Chemistry</i> , 2014, 83, 366-373.  | 2.6 | 22        |
| 4  | Innovative in Vitro Method To Predict Rate and Extent of Drug Delivery to the Brain across the Bloodâ€‘Brain Barrier. <i>Molecular Pharmaceutics</i> , 2013, 10, 3822-3831.  | 2.3 | 19        |
| 5  | Modified Nonsink Equation for Permeability Estimation in Cell Monolayers: Comparison with Standard Methods. <i>Molecular Pharmaceutics</i> , 2014, 11, 1403-1414.  | 2.3 | 18        |
| 6  | Semisynthesis, Cytotoxic Activity, and Oral Availability of New Lipophilic 9-Substituted Camptothecin Derivatives. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 651-655.  | 1.3 | 17        |
| 7  | Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 366, 96-104.   | 1.3 | 9         |
| 8  | Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making. <i>Pharmaceutics</i> , 2021, 13, 709.   | 2.0 | 9         |
| 9  | The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives. <i>Pharmaceutics</i> , 2021, 13, 1016.   | 2.0 | 9         |
| 10 | Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis. <i>Pharmaceutics</i> , 2022, 14, 654.  | 2.0 | 9         |
| 11 | Population pharmacokinetic model of lithium and drug compliance assessment. <i>European Neuropsychopharmacology</i> , 2016, 26, 1868-1876.   | 0.3 | 8         |
| 12 | Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2020, 109, 300-308.   | 0.7 | 7         |
| 13 | Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice. <i>Pharmaceutics</i> , 2020, 12, 975.   | 2.0 | 7         |
| 14 | Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series. <i>Pharmaceutics</i> , 2022, 14, 1010.   | 2.0 | 7         |
| 15 | Population pharmacokinetic/pharmacodynamic modelling of the effects of axomadol and its Oâ€‘demethyl metabolite on pupil diameter and nociception in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 92-107.                       | 1.1 | 6         |
| 16 | Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 905-915.                          | 1.1 | 6         |
| 17 | Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 117, 193-203. | 1.9 | 5         |
| 18 | Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. <i>Pharmaceutics</i> , 2020, 12, 1226.  | 2.0 | 4         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Estimators and confidence intervals of $\int_0^{\infty} f(x) dx$ using bootstrap methodology for the comparison of dissolution profiles. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 212, 106449.                                | 2.6 | 3         |
| 20 | Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors. <i>Cancers</i> , 2021, 13, 5049.   | 1.7 | 2         |
| 21 | Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. <i>Drug Metabolism and Drug Interactions</i> , 2020, 35, .  | 0.3 | 1         |
| 22 | Pharmacometric characterization of entero-hepatic circulation processes of orally administered formulations of amiodarone under complex binding kinetics. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 174, 106198.                | 1.9 | 1         |
| 23 | Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease. <i>Pharmaceutics</i> , 2020, 12, 1147.  | 2.0 | 0         |
| 24 | Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. <i>Drug Metabolism and Personalized Therapy</i> , 2021, .   | 0.3 | 0         |
| 25 | Quantitative assessment of the exposure–efficacy relationship of glucocerebrosidase using Markovian elements in Gaucher patients treated with enzyme replacement therapy. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2727-2737. | 1.1 | 0         |